



Haematology Society of  
Australia and New Zealand  
New Zealand Annual Branch Meeting

AbbVie invites you to the

# AbbVie Sponsored Breakfast

Monday 12th April at 7.15am  
Breakfast served at 6.45am

abbvie

## *The changing face of AML*

*Patient selection in a targeted therapy environment*



**Dr Courtney DiNardo**  
The University of Texas, MD Anderson Cancer Centre,  
Houston, USA

Dr. Courtney DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. Dr. DiNardo has experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies to innovative investigator-initiated Phase II trials, to confirmatory randomized Phase III trials. Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).

Park Hyatt Auckland | 11 - 13 April 2021